Gossamer Bio, Inc. (NASDAQ:GOSS) Stock Has Average Target Price of $256.00 According to Analysts

Posted by Brenda Bartman on Oct 15th, 2026

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS – Get Free Report) have been given an average rating of “Hold” by the ten research firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $256.00.

A number of research analysts have recently weighed in on the company. Chardan Capital began coverage on Gossamer Bio in a research report on Tuesday. They set a “buy” rating on the stock. Wall Street Zen downgraded shares of Gossamer Bio from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a report on Tuesday, July 28th. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Finally, Weiss Ratings raised shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th.

Read Our Latest Report on GOSS

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. ADAR1 Capital Management LLC bought a new position in Gossamer Bio in the 2nd quarter worth $35,000. Hsbc Holdings PLC purchased a new stake in Gossamer Bio in the 1st quarter worth $38,000. SG Americas Securities LLC raised its holdings in Gossamer Bio by 73.4% during the first quarter. SG Americas Securities LLC now owns 128,568 shares of the company’s stock valued at $42,000 after acquiring an additional 54,439 shares during the period. Bank of America Corp DE bought a new stake in Gossamer Bio during the second quarter valued at about $65,000. Finally, Ieq Capital LLC bought a new stake in Gossamer Bio during the second quarter valued at about $97,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Price Performance

NASDAQ:GOSS opened at $8.90 on Thursday. Gossamer Bio has a one year low of $8.77 and a one year high of $309.60. The business has a fifty day moving average price of $12.14 and a 200-day moving average price of $17.08. The firm has a market capitalization of $54.38 million, a price-to-earnings ratio of -0.16 and a beta of 2.21.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.